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Physical therapy in patients with Alzheimer’s 
disease: a systematic review of randomized 
controlled clinical trials
Fisioterapia em pacientes com doença de Alzheimer: uma revisão sistemática de ensaios 
clínicos randomizados controlados
Fisioterapia en pacientes con enfermedad de Alzheimer: una revisión sistemática de ensayos 
clínicos aleatorizados controlados
Carlos Leonardo Sacomani Marques1, Maria Helena Borgato2, Eduardo de Moura Neto3, Rodrigo Bazan4, 
Gustavo José Luvizutto5
ABSTRACT | The objective of this study is to evaluate the 
effects of physical therapy on the cognitive and functional 
capacity of patients with Alzheimer’s Disease (AD). This is 
a systematic review of randomized or quasi-randomized 
clinical trials, using the descriptors: AD, dementia and physical 
therapy. Two studies were included with a total of 207 
participants. In study 1, no statistically significant difference 
was found on the mini-mental state examination (MMSE) 
(MD 0.0, 95%CI −5.76 to 5.76), neuropsychiatric inventory 
(MD −4.50, 95%CI −21.24 to 12.24) and Pfeffer instrumental 
activities questionnaire (MD 0.0 95%CI −6.48 to 6.48). In 
study 2, there was no statistically significant difference on 
the MMSE (MD −1.60, 95% CI −3.57 to 0.37), clock-drawing 
test (MD −0.20, 95%CI −0.61 to 0.21) and Alzheimer’s Disease 
Assessment Scale – cognitive subscale (MD 1.0, 95%CI −2.21 to 
4.21) after 12 months. There was no consistent evidence on the 
effectiveness of physiotherapeutic intervention in improving 
cognitive function and functional capacity of patients with 
AD. More studies should be conducted for better evidence.
Keywords | Alzheimer’s Disease; Cognition; Activities of Daily 
Life; Physical Therapy; Systematic Review.
RESUMO | O objetivo do estudo é avaliar os efeitos 
da fisioterapia na capacidade cognitiva e funcional de 
pacientes com doença de Alzheimer (DA). Trata-se de 
revisão sistemática de ensaios clínicos randomizados 
ou quasi-randomizados utilizando os descritores: DA, 
demência e fisioterapia. Dois estudos foram incluídos, com 
um total de 207 participantes. No Estudo 1, não houve 
diferença estatisticamente significativa no miniexame 
do estado mental (MEEM) (MD 0,0, IC 95% 5,76−5,76), 
inventário neuropsiquiátrico (MD −4,50, IC 95% 12,24−21,24) 
e questionário de atividades instrumentais Pfeffer (MD 0,0 
IC 95% −6,48 a 6,48). No Estudo 2, não houve diferença 
estatisticamente significativa no MEEM (MD −1,60, IC 
95% −3,57 a 0,37), teste do desenho do relógio (MD −0,20, 
IC95% −0,61 a 0,21) e escala de avaliação da doença de 
Alzheimer – subitem cognição (MD 1,0, IC95% −2,21 a 
4,21) após 12 meses. Não houve evidência consistente 
da eficácia da intervenção fisioterapêutica na melhora 
da função cognitiva e capacidade funcional na DA. 
Recomenda-se a produção de mais estudos para encontrar 
possíveis evidências.
Descritores | Doença de Alzheimer; Cognição; Atividades da 
Vida Diária; Fisioterapia; Revisão Sistemática; Ensaios Clínicos.
RESUMEN | El presente estudio tiene como objetivo evaluar 
los efectos de la fisioterapia en la capacidad cognitiva y 
funcional de pacientes con enfermedad de Alzheimer (EA). 
Se trata de una revisión sistemática de ensayos clínicos 
aleatorizados o casi-aleatorizados, en que se utilizó los 
descriptores: EA, demencia y fisioterapia. Se incluyeron dos 
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estudios, con un total de 207 participantes. En el Estudio 1, no hubo 
diferencias estadísticamente significativas en el Miniexamen del 
estado mental (MEEM) (MD 0,0, IC 95%: 5,6 –5,76), en el inventario 
neuropsiquiátrico (MD –4,50, IC 95%: 12,24 –21,24) y en el cuestionario 
de actividades instrumentales de Pfeffer (MD: 0,0 IC 95% IC: –6,48 
a 6,48). En el Estudio 2, no hubo diferencias estadísticamente 
significativas en el MEEM (MD −1,60, IC 95% −3,57 a 0,37), el test 
de diseño del reloj (MD −0,20, IC 95% −0,61 a 0,21) y la escala de 
evaluación de la enfermedad de Alzheimer: subítem de cognición 
(MD 1,0, IC 95% −2,21 a 4,21) tras 12 meses. No hubo evidencia 
consistente de la eficacia de la intervención fisioterapéutica en la 
mejora de la función cognitiva y de la capacidad funcional en la 
EA. Se recomienda realizar estudios adicionales para encontrar 
posibles evidencias.
Palabras clave | Enfermedad de Alzheimer; Cognición; Actividades 
de la Vida Diaria; Fisioterapia; Revisión Sistemática.
INTRODUCTION
As a consequence of changes in the epidemiological and 
demographic profiles of the population, there was an increase 
in the number of chronic diseases, mainly cognitive diseases 
including Alzheimer’s disease (AD)1-3. AD is characterized 
by neurodegenerative changes associated with gradual deficits 
in cognitive function, memory, and behavioral changes. 
AD has a slow and progressive evolutionary characteristic, 
leading to a decline in the long-term functional capacity4. 
The main pathophysiological finding is the deposition of 
beta-amyloid protein, abnormal protein filaments, and 
synaptic decline with the activation of glial cells, including 
inflammatory processes in the central nervous system5.
During the neuropathological progression of AD, the 
cholinergic activity is reduced, thereby affecting cognitive 
function and behavior owing to the lack of cholinergic 
neurons in the nucleus basalis of Meynert and significant 
reduction of gray matter in the bilateral prefrontal cortex, 
parietal lobe, and cingulate gyrus6. Genetic aspects are of 
great importance in the etiopathogenesis of AD, leading to 
somatic mutation in the tissues7. Among the main disabilities 
observed in AD, dementia, which affects about one in six 
individuals over 80 years of age, decreases the functional 
capacity, autonomy, and quality of life, thereby creating a 
great socioeconomic impact on the public health system.
AD must be approached by a multidisciplinary 
team using pharmacological and non-pharmacological 
interventions aimed at delaying the reduction in cognitive 
function, minimizing functional disabilities, as well as 
treating the non-cognitive manifestations. Among the 
non-pharmacological treatments, physical therapy plays 
an important role in reducing complications of AD. It 
mainly involves the use of aerobic or anaerobic exercises 
aimed to improve functional capacity, reduce medication 
used, decrease the risk of falls, and minimize the functional 
deficits during the course of the disease8.
Multiple factors involved in AD lead to reduced 
autonomy and independence, thus increasing the risk of 
hospitalization, institutionalization, and death. Physical 
exercise can reduce the risk of disability and prevent 
cognitive decline and memory9,10. Although current 
evidence remains insufficient to conclude that physical 
therapy is effective for AD, the non-pharmacological 
approach continues to be a promising area of research 
for AD treatment. This review is important for physical 
therapists to be aware of evidence-based strategies available 
to provide the most effective physical therapy in AD.
Therefore, the aim of the review is to evaluate the 
efficacy of physical therapy in the cognitive and functional 
aspects of AD.
METHODOLOGY
We adhered to methods described in the Cochrane 
Handbook for Systematic Reviews of Interventions11. 
Our report adheres to the Preferred Reporting Items 
for Systematic Reviews and Meta-analyses (PRISMA).
Eligibility criteria
• Study designs: randomized controlled trials (RCTs) 
and quasi-randomized controlled trials (RCTs)
• Participants: patients with Alzheimer’s disease
• Interventions: physical therapy involving aerobic or 
anaerobic exercises versus control group; physical 
therapy involving multimodal interventions; and 
physical therapy associated with drug treatment 
versus physical therapy alone.
• Control groups: placebo or standard rehabilitation
• Outcomes:
• Global cognitive function tests: Any test or 
measure that evaluates cognitive function, such 
as the mini mental state examination (MMSE); 
Wechsler memory digit span forward and 
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digit span backward tests; Montreal cognitive 
assessment (MOCA); clock-drawing test; or 
neuropsychiatric inventory.
• Functional skills measured by any specific 
instrument, such as the timed up and go test, 
or the 6-minute walk test;
• Functional ability through activities of daily 
living measured by validated instruments such 
as the Barthel index or Pfeffer functional 
activities questionnaire;
• Balance measured by the Berg scale or 
Tinetti test;
• Quality of life measured through short form 
health survey (SF-36);
• Adverse events (such as orthostatic 
hypotension, fatigue, vertigo, dehydration, 
insomnia, syncope, etc).
Data sources and electronic searches
Using the Medical Subject Headings (MeSH), the 
terms selected were “Alzheimer’s disease,” “dementia,” 
“physiotherapy”, “non-pharmacological”, “exercise”, 
“rehabilitation”, “therapy”, “training”, and “physical 
activity”. The search strategy was run in Medline, 
EMBASE, Cochrane Central Register of Controlled Trials 
(CENTRAL), LILACS, and Scopus. The search strategy for 
Ovid MEDLINE was: (Alzheimer Disease OR Alzheimer 
Sclerosis OR Alzheimer Syndrome OR Alzheimer Type 
Senile Dementia OR ATD OR Alzheimer Type Dementia 
OR Senile Dementia OR Primary Senile Degenerative 
Dementia OR Acute Confusional Senile Dementia OR 
Presenile Dementia OR Late Onset Alzheimer Disease OR 
Focal Onset Alzheimer Disease OR Familial Alzheimer 
Disease OR FAD OR Presenile Alzheimer Dementia OR 
Early Onset Alzheimer Disease) AND (Physical Therapy 
Specialty OR Physiotherapy Specialty). This strategy was 
adapted for the other databases and run up to October 
2018. No language restrictions were imposed.
Selection of studies
Two authors of the review selected the titles and 
abstracts of the articles obtained from the electronic 
databases and excluded those that presented irrelevant 
outcomes for the review. Only complete articles were 
selected. Two independent authors screened the articles 
to identify the inclusion criteria and the studies that 
were ineligible for this review. If there was disagreement 
between the evaluators of the articles, a third evaluator 
was consulted.
Data extraction
Reviewers underwent calibration exercises, and worked 
in pairs to independently extract data from included 
studies. They resolved disagreement by discussion or, 
if necessary, with third party adjudication. Data were 
extracted using a pre-tested data extraction form: study 
design; participants; interventions; comparators; outcome 
assessed; and relevant statistical data. The authors of the 
included studies were contacted via e-mail for clarification 
on missing data or for more information.
Risk of bias assessment
Two review authors (CLSM and GJL) independently 
assessed the risk of bias for each study, using the criteria 
outlined in the Cochrane Handbook for Systematic Reviews 
of Interventions12 and PEDro score (high quality=PEDro 
score 6-10; fair quality=PEDro score 4-5; poor quality=PEDro 
score≤3). We resolved disagreements by discussion or by 
consultation with another review author (RB). We assessed 
risk of bias according to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded the risk of bias for each domain as high, 
low, or unclear and provided information from the study 
report, together with justification for our judgment, in 
the “Risk of bias” tables.
Data synthesis and statistical analysis
We analyzed all outcomes as continuous variables. 
We presented the results as mean of differences (MD) 
along with 95% confidence intervals, using fixed-
effects models. The unit of analysis was each participant 
recruited for review.
We assessed variability in results across studies by 
using the I2 statistic and the p-value for the chi square 
test of heterogeneity provided by Review Manager. We 
used Review Manager (RevMan) (version 5.3; Nordic 
Cochrane Centre, Cochrane) for all analyses.
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As we identified an inadequate number of studies, we 
did not perform a sensitivity (e.g., low versus high risk 
of bias) nor a subgroup analysis.
RESULTS
Study selection
A total of 38 articles (21 in Medline, 12 in EMBASE, 
2 in CENTRAL and 3 in LILACS) were identified in 
the databases (Figure 1). After analyzing the titles and 
abstracts, full copies of the 13 complete studies eligible 
for inclusion in the review were obtained. Eleven studies 
were excluded12-22 from the review because they were 
experimental studies, case series or cohort studies, or 
reviews. Two studies23,24 – one23 randomized clinical trial 
and one24 quasi-randomized clinical trial – with a total of 
207 participants achieved the minimum methodological 
requirements and were included in this review.
38 articles found 
in all databases
O andditional records 
identied in other sources
No duplicate records
38 selected  articles 25 articles were 
excluded
13 articles assessed 
for eligibility 
2 studies included 
in qualitative 
synthesis
2 studies included 
in the meta-analysis 
representation
4 articles 
presented 
review design
5 articles 
presented 
cohort design
1 article presented 
case series design
1 article 
presented 
experimental 
study design
11 articles 
excluded, due to 
the following 
reasons:
Figure 1. Flowchart of systematic review
Study characteristics
Andersen et al.24 evaluated the use of donezepil (once a 
day, 5 to 10 mg) associated with the stimulation program 
(maximum of 250 sessions per year) compared to the 
placebo group in 180 participants with AD and MMSE 
score greater than or equal to 10 points. The age range 
was 65-100 years23. Nascimento et al.25 evaluated an 
interdisciplinary rehabilitation program compared to the 
group that did not receive rehabilitation in 27 patients 
with Diagnosis of AD, dementia and hearing ability 
sufficient to comply with the procedures24.
Type of intervention and follow-up
Patients in the study by Andersen et al.24 underwent 
treatment with a program of stimulation therapy including 
physical, cognitive, sensory, and social stimulation 
activities. The program systematically included activities of 
daily living such as walking, housework, regular reading of 
books and newspapers, training in specific rooms, dancing, 
crossword puzzles, music therapy, and regular participation 
in community social life. More sophisticated activities 
such as reminiscence groups, Sudoku, aromatherapy, 
and sensory garden were also added, which allowed 
participants to move freely. This therapy was performed 
for a minimum of 30 minutes, 5 days a week, for a year 
(maximum of 250 sessions per year). All participants 
were prescribed donepezil or placebo (5 mg) once a day, 
progressing to 10 mg after 4 days. Adverse events were 
systematically recorded and the patients were monitored 
for 12 months23.
Patients in the study by Nascimento et al.25 underwent 
treatment through an interdisciplinary program that 
consisted of cognitive therapy, occupational therapy, 
and aerobic physical activity (moderate intensity). The 
intervention was performed three times a week in sessions 
composed of activities that benefited functional capacity, 
such as flexibility (stretching), muscular endurance, 
and balance. Various types of stimulation were applied, 
such as different photos placed on the wall and objects 
of different colors to be identified, memory sets and 
simple calculations, all combined with exercises. All 
participants performed the tasks together to stimulate 
social interaction and under the supervision of 3 to 6 
physical educators or physical therapists. The heart rate 
during the session remained between 60% and 80% of 
the maximum heart rate. The follow-up lasted 6 months 
for all participants24.
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Type of study participants
Participants in the study by Andersen et al.24 were 
individuals aged 65-100 years with a recent diagnosis of 
AD and an MMSE score greater than or equal to 10 points. 
In the initial evaluation, 43 participants had an MMSE 
between 10 and 20 points, 92 participants scored between 
21 and 25 points, and 52 participants scored 26 or higher. 
Nascimento et al.25 assessed patients with a clinical diagnosis 
of AD according to the NINCDS-ADRDA Alzheimer’s 
criteria (1984) and dementia assessment according to the 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV-R); ability to travel, preserved vision, and 
hearing ability sufficient to comply with the test procedures 
(spectacles and/or hearing aids were admissible). A physician 
trained in geriatric psychiatry confirmed the diagnosis and 
included patients with mild or moderate AD, and supervised 
all cognitive and neuropsychiatric evaluations while blinded 
to the allocation of patients in the treatment groups.
Type of outcomes
Andersen et al.24 assessed patients using the following 
tests/metrics: changes in the MEEM score; Alzheimer’s 
disease assessment scale, cognition (ADAS-Cog); and 
clock-drawing test. Nascimento et al.25 evaluated the 
MMSE, neuropsychiatric inventory (NPI), and Pfeffer 
functional activity questionnaire.
Risk of bias in included studies
Figure 2 describes the risk of bias assessment for 
the RCTs. The major issues regarding risk of bias were 
problems of generation of allocation, concealment 
of randomization and blinding of participants and 
personnel in the study by Nascimento et al.24 The PEDro 
score for Andersen et al.24 was 9 (high quality) and for 
Nascimento et al.25 was 7 (high quality).
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data attrition bias
Selective reporting (reporting bias)
Other bias
Figure 2. Risk of bias in included studies
Outcomes
Cognitive function
A statistically significant difference was found in the 
neuropsychiatric inventory for the pre-treatment physical 
activity group compared to control (MD, 11.0; 95% confidence 
interval [CI], 2.27-19.73). However, no statistically significant 
difference was found related to the MMSE scores or the 
neuropsychiatric inventory between the pre- and post-
treatment groups (MMSE: MD, 0.0; 95% CI, −5.76-5.76; 
NPI: MD, −4.50; 95% CI, −21.24-12.24; Figure 3A)24.
There was no statistically significant difference at 
baseline between the experimental and placebo groups 
in the MMSE (MD, −0.40; 95% CI, −2.22-1.42), 
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clock-drawing test (MD, 0.0; 95 % CI, −0.45-0.45), and 
ADAS-Cog (MD, 2.10; 95% CI, −1.13-5.33) scores 
(Figure 4A). After 4 months of treatment, there was 
no statistically significant difference in the MMSE 
(MD −0.90; 95% CI, −2.58-0.78), clock-drawing test 
(MD, −0.30; 95% CI, −0.71-0.11), and ADAS-Cog 
(MD, 2.90; 95% CI, −0.06-5.86) scores between the 
groups (Figure 4B). After 8 months of treatment, there 
was no statistically significant difference in the MMSE 
(MD, −0.70; 95% CI, −2.53-1.13) and ADAS-Cog 
(MD, 0.90; 95% CI, −2.58-4.38) scores between groups. 
The clock-drawing test score was significantly different 
between the groups (MD, −0.50; 95% CI, −0.96 to 
−0.04) (Figure 4C). After 12 months of treatment, 
there was no statistically significant difference in the 
MMSE (MD, −1.60; 95% CI, −3.57-0.37), clock test 
(MD, −0.20; 95% CI, −0.61-0.21), and ADAS-Cog 
(MD, 1.0; 95% CI, −2.21-4.21) scores between groups 
(Figure 4D)23.
Activities of daily living
No statistically significant difference was found in 
the Pfeffer instrumental activities questionnaire between 
the pre- and post- treatment groups (MD, 0.0; 95% 
CI, −6.48-6.48) (Figure 3B). (A) Differences between 
control and experimental groups for cognitive function 
before and after treatment with physical activity; (B) 
Differences between control and physical activity groups 
for activities of daily living before and after treatment 
with physical activity
Figure 3. Cognitive and physical function before and after physical therapy
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ADAS-Cog
ADAS-Cog
Clock-drawing test
Clock-drawing test
Clock-drawing test
Clock-drawing test
ADAS-Cog
ADAS-Cog
Donezepil
Donezepil
Donezepil
Donezepil
Figure 4. Cognitive function before and after physical therapy
(A) Cognitive function difference at baseline between the experimental and placebo groups; (B) Cognitive function difference at 4 months between the experimental and placebo groups; (C) Cognitive 
function difference at 8 months between the experimental and placebo groups; (D) Cognitive function difference at 12 months between the experimental and placebo group.
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Effects of interventions
See summary of findings (Tables 1 and 2).
Table 1. GRADE evidence profile of cognitive function and activities of daily living in patients with AD for received physical therapy 
versus control group
Outcomes Mean difference (95% CI)
Number of 
participants (studies)
Quality of the 
evidence (GRADE)
Cognitive function
Mini-mental state examination
Neuropsychiatric inventory
Nascimento 2012 study
Follow-up: last day of therapy (discharge)
Before treatment
MMSE 0.60 (−4.46 to 5.66)
NPI 11.00 (2.27 to 19.73)
After treatment
MMSE 0.0 (−5.76 to 5.76)
NPI −4.50 (−21.24 to 12.24)
27 (1 study)a,b,c,d,e
⊕⊝⊝⊝  
very low
Daily life functions
Pfeffer Instrumental Activities Questionnaire
Nascimento 2012 study
Follow-up: last day of therapy (discharge)
Before treatment
Pfeffer 5.39 (−2.45 to 13.23)
After treatment
Pfeffer 0.00 (−6.48 to 6.48)
27 (1 study)a,b,c,d,e
⊕⊝⊝⊝ 
very low
GRADE Working Group grades of evidence
High quality: Further investigations are very unlikely to change our 
confidence in the estimate of effect
Moderate quality: Further investigations are likely to impact our 
confidence on the estimate of effect and may change the estimate
Low quality: Further estimate of effect very likely to impact our 
confidence on the estimate of effect and is likely to change the estimate
Very low quality: We are very uncertain about the estimate
a: Meta-analysis could not be performed; only 1 study could be represented graphically; b: Quality was downgraded by 1 level because of very serious imprecision (selection bias, performance bias, small 
sample size); c: Although the confidence interval was narrow in some of the scales that evaluated the primary outcome, the magnitude of effect was controversial; d: Quality was downgraded by 1 level 
for uncertainty on both publication bias and heterogeneity (Heterogeneity: Chi²=5.40, df=3 (p=0.14); I²=44%), as included studies were insufficient to allow this analysis; e: Risk of bias in four domains 
was classified as low, and in three as high.
Table 2. GRADE evidence profiles of cognitive function in patients with AD for received physical therapy associated with drug treatment 
versus control group
Outcomes Mean difference (95% CI)
Number of 
participants 
(studies)
Quality of the 
evidence 
(GRADE)
Cognitive function
Mini-mental state examination
Cock-drawing test
ADAS-Cog
Andersen 2012 study
Follow-up:
4 months, 8 months and 12 months after treatment
Baseline
MMSE −0.40 (−2.22 to 1.42)
Clock-drawing test 0.00 (−0.45 to 0.45)
ADAS-Cog 2.10 (−1.13 to 5.33)
4 months
MMSE −0.90 (−2.58 to 0.78)
Clock-drawing test −0.30 (−0.71 to 0.11)
ADAS-Cog 2.90 (−0.06 to 5.86)
8 months
MMSE −0.70 (−2.53 to 1.13)
Clock-drawing test −0.50 (−0.96 to −0.04)
ADAS-Cog 0.90 (−2.58 to 4.38)
12 months
MMSE −1.60 (−3.57 to 0.37)
Clock-drawing test −0.20 (−0.61 to 0.21)
ADAS-Cog 1.00 (−2.21 to 4.21)
180 (1 study)a,b,c,d,e
⊕⊕⊝⊝ 
Moderate
GRADE Working Group grades of evidence
High quality: Further investigations are very unlikely to change 
our confidence in the estimate of effect
Moderate quality: Further investigations are likely to impact our 
confidence on the estimate of effect and may change the estimate
Low quality: Further investigations are very likely to important our 
confidence on the estimate of effect and is likely to change the 
estimate
Very low quality: We are very uncertain about the estimate
a: Meta-analysis could not be performed; only 1 study could be represented graphically; b: Quality was downgraded by 1 level because of very serious imprecision (detection bias and CI include effects 
suggesting benefits, as well as damage); c: The confidence interval was narrow in some of the scales that evaluated the primary outcome; the scores for the scales used in the study are similar for the 
two groups studied, at baseline and follow-up; d: There is no publication bias because unfavorable results and a low heterogeneity were presented: Chi²=1.81, df=2 (p=0.40); I²=0%; e: Risk of bias in all 
domains was generally classified as low.
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DISCUSSION
Main findings
This review found a limited number of randomized 
clinical trials that demonstrate the efficacy of physical 
therapy treatment in improving the cognitive function 
of patients with Alzheimer’s disease. In the study by 
Nascimento et al.25, the authors observed that there was 
no benefit of physical therapy in improving the cognitive 
and functional function in patients with AD. While few 
studies have demonstrated the positive impact of physical 
therapy in patients with AD, we can infer that physical 
inactivity is related to risk factors such as smoking, 
inadequate eating habits, alcoholism, emotional stress, 
and cognitive impairment24. Some risk factors are also 
associated with a higher risk of cognitive decline, such 
as chronic diseases, hypercholesterolemia, and sedentary 
lifestyle, and may be reversed or attenuated by regular 
physical exercise25.
Studies have shown that active people who perform 
some type of physical exercise have a lower risk of being 
affected by cognitive deficits than sedentary people, 
thereby acquiring increased brain plasticity process and 
resistance of the brain to lesions, as well as improving 
learning and functional capacity26,27.
The benefit caused by physical exercise in cognitive 
functions is due to the improvement in cardiovascular 
function when there is a progressive decrease in oxygenation 
and tissue hypoxia over time leading to a cognitive decline. 
Physical activity and cardiorespiratory exercises minimize 
cognitive dysfunction in the acute phase of AD28. The 
maximal oxygen consumption (VO2 max) is reduced 
in AD, and exercise has great benefit in cognition as it 
increases the VO2 max in this population29. Studies have 
demonstrated an improvement in memory and executive 
function with an increase in the cardiorespiratory capacity, 
and its benefits are related with improvements in memory 
performance and changes in brain volume, manly in the 
bilateral hippocampus volume30,31.
Regular physical activity has been recommended for 
the prevention and treatment of cardiovascular diseases 
(hypertension, insulin resistance, diabetes mellitus, 
dyslipidemia, and obesity), where physical inactivity and 
unfavorable habits are directly linked to the development 
of cognitive decline32. A meta-analysis of 54 randomized 
controlled trials examined the effect of aerobic exercise 
on blood pressure and found that this exercise modality 
reduces the systolic and diastolic pressures by 3.8 mmHg 
and 2.6 mmHg, respectively. In this sense, a reduction of 
only 2 mmHg in the diastolic pressure can substantially 
reduce the risk of chronic diseases and cognitive 
decline33. Aerobic exercise benefits the functional ability 
in individuals with early-stage AD. Furthermore, we 
found indirect evidence that exercise-related increases 
in cardiorespiratory fitness may be important to improve 
memory performance and reduce hippocampal atrophy34.
In the study by Andersen et al.24, donezepil associated 
with rehabilitation did not have a significantly different 
effect on the test scores, compared to when physical 
therapy was used alone. The multidisciplinary treatment 
for AD leads to improvement in the quality of life of the 
patient and his/her family, reducing cognitive deficits and 
behavioral changes. Over the years, pharmacotherapy 
in the treatment of AD has greatly evolved, with 
anticholinesterase drugs (donezepil, rivastigmine, 
epstatigmine, and galantamine) acting on the symptoms 
of the disease by improving the healthcare network. 
Complementing this therapy with rehabilitation could 
enhance the action of pharmacological treatment, leading 
to an improvement in cognitive performance, behavior, 
and quality of life35. However, these studies are limited 
by short follow-up period, retrospective design, poorly 
defined controls, and small sample sizes. In our study, 
there was no difference in cognitive performance between 
donepezil and placebo groups, regardless of standard 
pacing or therapy. The activities are very different in this 
study and do not follow the same line of learning; in 
this way, individuals would hardly have positive results 
regarding the effectiveness of the method.
Strengths and limitations
In the two studies included in this review, the 
patient groups, interventions, and relevant outcomes 
were addressed to prove the efficacy of physical therapy 
treatment using the MMSE score as the primary endpoint 
for cognitive function. The review does not report 
secondary outcomes such as disability and functional 
skills measured by specific instruments, as the timed 
up and go and 6-minute walk test scores; functional 
capacity through activities of daily living measured by 
validated instruments, such as the Barthel’s index and 
Pfeffer functional activities questionnaire score; balance 
measured by the mean scores of the Berg and Tinetti 
scales; and quality of life through the SF-36 score.
Only two studies were included in this review; the 
total size was small, although a majority of the domains 
Fisioter Pesqui. 2019;26(3):311-321
320
evaluated were classified as presenting low risk of bias 
in relation to the methodological quality. The quality of 
evidence for the outcomes assessed in the two trials was 
very low, which lowered the quality from high to very 
low because of the presence of a serious risk of selection 
bias and inaccuracy (due to some events and small sample 
sizes). We cannot assess the publication bias and could 
not investigate heterogeneity as the included studies were 
insufficient to allow such analyses. The methodological 
quality of the two studies was reasonable, although the 
risk of selection bias was substantial (participants were 
distributed successively).
Implications
There was low quality of evidence to draw a consistent 
conclusion about the effectiveness and safety of physical 
therapy interventions in improving cognitive function 
and functional capacity in patients with Alzheimer’s 
disease. The applicability of these results may be 
compromised as they were obtained from studies of 
small sample sizes. This evaluation underlines the need 
for well-designed trials in this area. Future clinical 
trials should be methodologically adequate and include 
standardized outcome measures such as functional skills, 
balance, and quality of life tests.
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